SGLT2 inhibitor treatment for non-obstructive hypertrophic cardiomyopathy
Official title: SGLT-inhibitors in patients with hypertrophic cardiomyopathy
Funded at University of Pennsylvania · NIH-11161492 · Data updated 2026-11-12
This project will try giving an SGLT2 diabetes medicine to people with non-obstructive hypertrophic cardiomyopathy to see if it is safe and helps symptoms and heart energy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $685,334 |
| NIH project number | 5R33HL164376-03 |
| Project ID | NIH-11161492 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with symptomatic non-obstructive hypertrophic cardiomyopathy who can attend study visits, with or without diabetes, are the intended participants.
✕Less likely to help
People with obstructive HCM, severe kidney disease, or other contraindications to SGLT2 inhibitors may not be eligible or benefit from this treatment.
What this research studies
If I join, I would take an SGLT2 inhibitor (a diabetes medication that may protect the heart) even if I don't have diabetes and attend regular clinic visits. Doctors will use heart imaging, blood tests including markers of heart energy, and symptom questionnaires to track safety, feasibility, and early signs of benefit. The team will closely monitor kidney function and other side effects and compare measures from before and after treatment. Early results would guide whether larger trials are warranted.
Why it matters
Potential benefit: If successful, this approach could lessen symptoms and improve heart energy and outcomes for people with non-obstructive HCM.
How similar studies have gone: SGLT2 inhibitors have shown clear benefits in broad heart failure trials regardless of diabetes, but using them specifically for non-obstructive HCM is a novel application with limited prior data.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Day, Sharlene M — University of Pennsylvania
- Study coordinator: Day, Sharlene M
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.